Delta Asset Management LLC TN decreased its stake in Merck & Company, Inc. (NYSE:MRK) by 0.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,399 shares of the company’s stock after selling 100 shares during the period. Delta Asset Management LLC TN’s holdings in Merck & were worth $795,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of MRK. HM Capital Management LLC boosted its stake in Merck & by 0.4% in the first quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock valued at $236,000 after buying an additional 15 shares during the last quarter. RB Capital Management LLC boosted its stake in Merck & by 0.5% in the second quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock valued at $294,000 after buying an additional 23 shares during the last quarter. Baystate Wealth Management LLC boosted its stake in Merck & by 0.4% in the second quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock valued at $405,000 after buying an additional 27 shares during the last quarter. Bath Savings Trust Co boosted its stake in Merck & by 0.5% in the second quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock valued at $348,000 after buying an additional 28 shares during the last quarter. Finally, City Holding Co. boosted its stake in Merck & by 0.4% in the first quarter. City Holding Co. now owns 7,767 shares of the company’s stock valued at $494,000 after buying an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 73.00% of the company’s stock.

Merck & Company, Inc. (NYSE:MRK) traded down 0.17% on Wednesday, hitting $63.01. The stock had a trading volume of 2,064,120 shares. The company’s 50 day moving average price is $62.73 and its 200-day moving average price is $63.80. The company has a market cap of $171.85 billion, a price-to-earnings ratio of 34.11 and a beta of 0.80. Merck & Company, Inc. has a 12-month low of $58.29 and a 12-month high of $66.80.

Merck & (NYSE:MRK) last announced its earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. Merck &’s revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.93 EPS. Equities research analysts anticipate that Merck & Company, Inc. will post $3.88 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s payout ratio is currently 76.11%.

TRADEMARK VIOLATION NOTICE: “Merck & Company, Inc. (MRK) Stake Reduced by Delta Asset Management LLC TN” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/30/merck-company-inc-mrk-stake-reduced-by-delta-asset-management-llc-tn.html.

Several equities research analysts recently weighed in on the company. BidaskClub cut Merck & from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. BMO Capital Markets restated an “outperform” rating and set a $73.00 target price (down previously from $74.00) on shares of Merck & in a research note on Monday, July 24th. Credit Suisse Group decreased their target price on Merck & from $75.00 to $74.00 and set an “outperform” rating for the company in a research note on Wednesday. Zacks Investment Research cut Merck & from a “buy” rating to a “hold” rating in a research note on Thursday, May 25th. Finally, Jefferies Group LLC restated a “sell” rating and set a $51.00 target price on shares of Merck & in a research note on Wednesday, May 24th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $69.74.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.